Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

NCT07443397 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Whole-Brain Radiotherapy

Interventions

DRUG: Anlotinib
RADIATION: Whole-brain Radiotherapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences